New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
|
By LabMedica International staff writers Posted on 10 Mar 2025 |

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true for infants born as early as six to seven months of pregnancy, known as extremely preterm infants. These infants essentially continue their development outside the womb, facing even greater risks. Research in this population is complicated because conventional tests, such as blood draws, can be life-threatening due to the limited blood supply in these tiny patients. Now, a new methodology, combined with advanced techniques that analyze multiple molecular markers, is enabling researchers to gain valuable insights into the immune systems of extremely preterm infants more safely.
Researchers believe that early exposures to infections and environmental factors play a crucial role in shaping immune function later in life, though the exact impact of premature birth on the immune system is still under investigation. It was once thought that infant immune systems were not fully mature at birth, but accumulating evidence suggests that full-term babies are born with functioning immune systems, albeit different from those of adults. For preterm infants, determining whether this is also true has been challenging. Immune system studies typically require blood samples, and standard research methods use between 10 to 50 milliliters of blood. Collecting that amount from preterm infants could be harmful, draining their blood supply. Now, with only two drops of blood, researchers at Yale School of Medicine (YSM, New Haven, CT, USA) have demonstrated that preterm babies possess unique immune systems capable of responding to threats both before and after birth. This research, published in Science Translational Medicine, marks a key step in understanding the immune systems of extremely preterm infants, which is vital for improving care for this vulnerable group.
In their study, YSM researchers combined a protocol developed by Swedish researchers with advanced molecular techniques, enabling them to gather substantial data from just two drops of blood. Collaborating with Yale’s NOURISH team, the researchers collected blood samples from 10 extremely preterm infants, ranging from their first week to two months of age. They then analyzed protein expression and cell types in these samples, comparing them to data from adults and full-term infants. The results showed that preterm infants have a full array of immune cells, similar to those in adults and full-term infants. These babies even had memory T and B cells, which the immune system uses to recognize and respond to previously encountered threats. This finding suggests that these preterm infants were not only reacting to environmental exposures but may have also developed immunity while still in the womb.
However, the development of immune cells in preterm infants differed from that in full-term infants. The researchers observed that protein pathways and cell types related to inflammation were more active in extremely preterm infants, and this inflammation persisted for a longer period than in full-term infants. Around half of the preterm infants in the study had been exposed to an infection in the placenta before birth. These infants showed even higher levels of inflammatory cells in their blood than those who had not been exposed to such an infection. The long-term implications of these findings for the health of preterm infants remain unclear. While large-scale epidemiological studies suggest that early life exposure to pathogens and other immune triggers may increase the risk of conditions like asthma and irritable bowel syndrome, some early exposures also seem to protect against diseases like diabetes.
Though this small cohort has not yet provided enough data to establish definitive links, the researchers hope to shed more light on these potential connections. The team has now expanded their study to include around 250 preterm infants and is recruiting a comparable group of full-term infants for long-term observation, with plans to follow these infants for at least a year. They are also beginning to collect additional samples, including stool, skin, and nasal swabs, to further explore the development of the immune system in early life. The researchers remain optimistic about their findings and reassure parents that even preterm infants have the ability to combat infections and develop immunity despite arriving early into the world.
“The more premature an infant is, the more complications there are,” said Liza Konnikova, MD, PhD, an associate professor of pediatrics, immunobiology, and reproductive sciences at YSM and senior author of the study. “Our goal is to determine how long early-exposure impacts last, and whether they change your risk one way or another.”
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







